Viemed Healthcare 미래 성장

Future 기준 확인 4/6

Viemed Healthcare은 연간 수입과 매출이 각각 49.4%와 17.8% 증가할 것으로 예상되고 EPS는 연간 50.1%만큼 증가할 것으로 예상됩니다.

주요 정보

49.4%

수익 성장률

50.1%

EPS 성장률

Healthcare 수익 성장	58.0%
매출 성장률	17.8%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	06 Dec 2023

최근 미래 성장 업데이트

Recent updates

Some Investors May Be Worried About Viemed Healthcare's (TSE:VMD) Returns On Capital

Jul 08

Does This Valuation Of Viemed Healthcare, Inc. (TSE:VMD) Imply Investors Are Overpaying?

Mar 10

These 4 Measures Indicate That Viemed Healthcare (TSE:VMD) Is Using Debt Reasonably Well

Dec 09

Shareholders May Not Be So Generous With Viemed Healthcare, Inc.'s (TSE:VMD) CEO Compensation And Here's Why

Jun 04

Viemed Healthcare (TSE:VMD) Could Easily Take On More Debt

May 18

Viemed Healthcare, Inc.'s (TSE:VMD) Stock Is Going Strong: Is the Market Following Fundamentals?

Mar 03

I Ran A Stock Scan For Earnings Growth And Viemed Healthcare (TSE:VMD) Passed With Ease

Feb 16

Viemed Healthcare (TSE:VMD) Seems To Use Debt Rather Sparingly

Feb 03

If You Had Bought Viemed Healthcare (TSE:VMD) Shares Three Years Ago You'd Have Earned 319% Returns

Jan 21

Did Viemed Healthcare, Inc. (TSE:VMD) Insiders Sell Shares?

Jan 08

Should You Rely On Viemed Healthcare's (TSE:VMD) Earnings Growth?

Dec 22

Declining Stock and Solid Fundamentals: Is The Market Wrong About Viemed Healthcare, Inc. (TSE:VMD)?

Nov 25

수익 및 매출 성장 예측

TSX:VMD - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2025	249	N/A	20	N/A	1
12/31/2024	222	17	18	N/A	3
12/31/2023	183	11	17	N/A	3
9/30/2023	170	9	16	40	N/A
6/30/2023	156	7	11	34	N/A
3/31/2023	146	6	7	31	N/A
12/31/2022	139	6	5	28	N/A
9/30/2022	133	8	5	29	N/A
6/30/2022	127	9	0	26	N/A
3/31/2022	121	9	3	25	N/A
12/31/2021	117	9	3	22	N/A
9/30/2021	116	10	2	20	N/A
6/30/2021	120	11	10	22	N/A
3/31/2021	136	29	29	39	N/A
12/31/2020	131	32	22	35	N/A
9/30/2020	122	29	26	37	N/A
6/30/2020	108	29	24	35	N/A
3/31/2020	86	11	2	19	N/A
12/31/2019	80	9	6	19	N/A
9/30/2019	76	9	7	20	N/A
6/30/2019	73	8	8	19	N/A
3/31/2019	68	9	16	22	N/A
12/31/2018	64	10	16	22	N/A
9/30/2018	60	7	11	15	N/A
6/30/2018	56	9	10	13	N/A
3/31/2018	51	8	6	9	N/A
12/31/2017	47	8	8	12	N/A
9/30/2017	43	11	12	14	N/A
12/31/2016	31	1	N/A	6	N/A
12/31/2015	38	10	N/A	10	N/A
12/31/2014	23	9	N/A	8	N/A

애널리스트 미래 성장 예측

수입 대 저축률: VMD 의 연간 예상 수익 증가율( 49.4% )이 saving rate( 1.9% 보다 높습니다. ).

수익 vs 시장: VMD 의 연간 수익( 49.4% ) Canadian 시장( 15.5% 보다 빠르게 성장할 것으로 예상됩니다. 15.5% 연간).

고성장 수익: VMD 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: VMD 의 수익(연간 17.8% ) Canadian 시장( 7.1% 보다 빠르게 성장할 것으로 예상됩니다. 7.1% 연간).

고성장 수익: VMD 의 수익(연간 17.8% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: VMD 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2023/12/23 15:17
장 마감 주가	2023/12/21 00:00
수익	2023/09/30
연간 수익	2022/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Viemed Healthcare, Inc. 4 애널리스트 중 3 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Doug Cooper	Beacon Securities Limited
Vadim Merkulov	Freedom Broker
Brooks O'Neil	Lake Street Capital Markets, LLC

Viemed Healthcare 미래 성장

Future 기준 확인 4/6

주요 정보

최근 미래 성장 업데이트

Viemed Healthcare, Inc. Provides Revenue Guidance for the Fourth Quarter of 2024

Viemed Healthcare, Inc. Provides Revenue Guidance for the Third Quarter of 2024

Viemed Healthcare, Inc. Provides Revenue Guidance for the Second Quarter of 2024

Viemed Healthcare, Inc. Provides Earnings Guidance for the First Quarter of 2024

Consensus EPS estimates fall by 11%

Viemed Healthcare, Inc. Provides Revenue Guidance for Third Quarter of 2023

Recent updates

Viemed Healthcare, Inc. Provides Revenue Guidance for the Fourth Quarter of 2024

Viemed Healthcare, Inc. Provides Revenue Guidance for the Third Quarter of 2024

Viemed Healthcare, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Viemed Healthcare, Inc. Provides Revenue Guidance for the Second Quarter of 2024

Viemed Healthcare, Inc., Annual General Meeting, Jun 06, 2024

Viemed Healthcare, Inc. Provides Earnings Guidance for the First Quarter of 2024

Third quarter 2023 earnings: EPS misses analyst expectations

Is Viemed Healthcare (TSE:VMD) A Risky Investment?

Consensus EPS estimates fall by 11%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Viemed Healthcare, Inc. Provides Revenue Guidance for Third Quarter of 2023

Independent Director exercised options and sold CA$116k worth of stock

Consensus EPS estimates increase by 15%

The Returns On Capital At Viemed Healthcare (TSE:VMD) Don't Inspire Confidence

Consensus EPS estimates increase by 57%

CEO & Director exercised options and sold CA$133k worth of stock

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Viemed Healthcare, Inc. Provides Revenue Guidance for the Second Quarter of 2023

Investor sentiment improves as stock rises 15%

Consensus EPS estimates increase by 15%

Independent Director exercised options and sold CA$135k worth of stock

Investor sentiment improves as stock rises 19%

Consensus EPS estimates fall by 26%

Full year 2022 earnings: EPS misses analyst expectations

Does Viemed Healthcare (TSE:VMD) Have A Healthy Balance Sheet?

Viemed Healthcare, Inc. Wins Complete Overruling of Appealed Office of Inspector General Claims Resolving Multiyear Process with HHS and CMS

CEO & Director exercised options and sold CA$147k worth of stock

Independent Director exercised options and sold CA$206k worth of stock

Insufficient new directors

Consensus EPS estimates increase by 58%

Viemed Healthcare, Inc. Provides Revenue Guidance for the Year 2022

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Does Viemed Healthcare (TSE:VMD) Have A Healthy Balance Sheet?

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Viemed Healthcare, Inc. Announces Earnings Guidance for the Third Quarter of 2022

Viemed Announces Management Appointments

Some Investors May Be Worried About Viemed Healthcare's (TSE:VMD) Returns On Capital

Investor sentiment improved over the past week

Viemed Healthcare, Inc. Announces Publication of Peer-Reviewed NIVH Study Finding Treatment Reduces Healthcare Costs and Saves Lives

Viemed Healthcare, Inc.(NasdaqCM:VMD) dropped from Russell 2000 Dynamic Index

CEO & Director exercised options and sold CA$103k worth of stock

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Viemed Healthcare, Inc. Provides Revenue Guidance for the Second Quarter of 2022

Insufficient new directors

Viemed Healthcare, Inc., Annual General Meeting, Jun 09, 2022

Consensus forecasts updated

Investor sentiment improved over the past week

Viemed Healthcare, Inc. Provides Revenue Guidance for the First Quarter of 2022

Does This Valuation Of Viemed Healthcare, Inc. (TSE:VMD) Imply Investors Are Overpaying?

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

These 4 Measures Indicate That Viemed Healthcare (TSE:VMD) Is Using Debt Reasonably Well

Third quarter 2021 earnings released: EPS US$0.045 (vs US$0.072 in 3Q 2020)

Independent Chairman exercised options to buy CA$79k worth of stock.

Viemed Healthcare, Inc. Provides Earnings Guidance for the Third Quarter of 2021

Second quarter 2021 earnings released: EPS US$0.04 (vs US$0.50 in 2Q 2020)

Shareholders May Not Be So Generous With Viemed Healthcare, Inc.'s (TSE:VMD) CEO Compensation And Here's Why

Viemed Healthcare (TSE:VMD) Could Easily Take On More Debt

CEO & Director exercised options and sold CA$814k worth of stock

Consensus forecasts updated

First quarter 2021 earnings released: EPS US$0.043 (vs US$0.11 in 1Q 2020)

Viemed Healthcare, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal 2021

Analysts lower EPS estimates to US$0.25

Full year 2020 earnings released: EPS US$0.81 (vs US$0.23 in FY 2019)

Earnings beat expectations, revenue disappoints

Viemed Healthcare, Inc.'s (TSE:VMD) Stock Is Going Strong: Is the Market Following Fundamentals?

I Ran A Stock Scan For Earnings Growth And Viemed Healthcare (TSE:VMD) Passed With Ease

Commonwealth Primary Care ACO and Viemed Healthcare Announce an Innovative Chronic Respiratory Care and Sleep Management Alliance